CommercialCoverageMedium impact
08.02.32, Afamitresgene autoleucel (Tecelra®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
A new policy has been established for Afamitresgene autoleucel (Tecelra®), a pharmacy/drug product. This appears to be a new coverage policy that will take effect on March 24, 2025, likely establishing coverage criteria, prior authorization requirements, or billing guidelines for this medication.
Action Required
Before March 24, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Afamitresgene autoleucel (Tecelra®). Update billing systems and provider guidance as needed once full policy details are available.